ELOXX PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Payments to Acquire Debt Securities, Available-for-sale of $67.21 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2022-03-30
- ELOXX PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-12-31 was $11.17M.
- ELOXX PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-09-30 was $22.45M.
- ELOXX PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-06-30 was $24.67M.
- ELOXX PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2019-03-31 was $8.92M.
- ELOXX PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2019 was $67.21M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-12-31 | $11.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $33.62M derived: sum of 2 quarters · filed 2022-03-30 | $58.29M derived: sum of 3 quarters · filed 2022-03-30 | $67.21M 10-K · filed 2022-03-30 |
| 2019-09-30 | $22.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $47.12M derived: sum of 2 quarters · filed 2020-11-06 | $56.04M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $24.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $33.59M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $8.92M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |